Burden of Uncontrolled Severe Asthma With and Without Elevated Type-2 Inflammatory Biomarkers
The Journal of Allergy and Clinical Immunology: In Practice · 2024-04 · 12 (4) · 970-982
DOI: 10.1016/j.jaip.2023.12.021 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift The Journal of Allergy and Clinical Immunology: In Practice, 2024-04. Verfasst von Bo Ding und 8 weiteren Autor:innen. Beteiligte Einrichtung: BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden. Electronic address: Bo.Ding@astrazeneca.com. Hauptthemen laut MEDLINE: Asthma, Eosinophilia, Hypersensitivity. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca.
Abstract (Originalsprache)
BACKGROUND: Many patients with asthma have type-2 airway inflammation, identified by the presence of biomarkers, including history of allergy, high blood eosinophil (EOS) count, and high fractional exhaled nitric oxide levels. OBJECTIVE: To assess disease burden in relation to type-2 inflammatory biomarker status (history of allergy, blood EOS count, and fractional exhaled nitric oxide level) in patients with uncontrolled and controlled severe asthma in the NOVEL observational longiTudinal studY (NOVELTY) (NCT02760329). METHODS: Asthma diagnosis and severity were physician-reported. Control was defined using Asthma Control Test score (uncontrolled
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden. Electronic address: Bo.Ding@astrazeneca.com.
- BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, Md.
- Real World Data Science, BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom.
- Global Health Economics and Payer Evidence, AstraZeneca, Cambridge, United Kingdom.
- The Woolcock Institute of Medical Research and Macquarie University, Sydney, New South Wales, Australia.
- Respiratory Medicine Unit, Department of Translational Medicine, Università di Ferrara, Ferrara, Italy.
Förderung
- AstraZeneca
Zitieren
APA
Ding, B., Chen, S., Rapsomaniki, E., Quinton, A., Cook, W., Reddel, H. K., Papi, A., NOVELTY Scientific Community, & NOVELTY study investigators (2024). Burden of Uncontrolled Severe Asthma With and Without Elevated Type-2 Inflammatory Biomarkers. The Journal of Allergy and Clinical Immunology: In Practice, 12(4), 970-982. https://doi.org/10.1016/j.jaip.2023.12.021
Vancouver
Ding B, Chen S, Rapsomaniki E, Quinton A, Cook W, Reddel HK, et al. Burden of Uncontrolled Severe Asthma With and Without Elevated Type-2 Inflammatory Biomarkers. The Journal of Allergy and Clinical Immunology: In Practice. 2024;12(4):970-982. doi:10.1016/j.jaip.2023.12.021
BibTeX
@article{Ding2024,
author = {Ding, Bo and Chen, Stephanie and Rapsomaniki, Eleni and Quinton, Anna and Cook, William and Reddel, Helen K and Papi, Alberto and NOVELTY Scientific Community, NOVELTY Scientific Community and NOVELTY study investigators, NOVELTY study investigators},
title = {Burden of Uncontrolled Severe Asthma With and Without Elevated Type-2 Inflammatory Biomarkers},
journal = {The Journal of Allergy and Clinical Immunology: In Practice},
year = {2024},
volume = {12},
number = {4},
pages = {970--982},
doi = {10.1016/j.jaip.2023.12.021}
}
EUVIMED